Printer Friendly

AnGes MG, Osaka University, Aoki Undertake Co-development of Fully Bioabsorbable Stent.

Tokyo, Japan, Oct 15, 2005 - (JCNN) - AnGes MG announced on October 11 that it has launched a development project of next-generation stent in collaboration with Osaka University and Aoki, an Osaka-based precision component manufacturer.

In this project, the three partners will strive to develop a stent made of magnesium alloy. The new stent may help prevent the development of restenosis. Specifically, Osaka University will be responsible for animal experiments to evaluate the magnesium stent, Aoki will examine the magnesium processing technology, and AnGes MG will design the form of stent while considering conditions for NF-kappa B decoy oligodeoxynucleotide coating.

Adopted by the Ministry of Economy, Trade and Industry as one of Consortium R&D projects for regional revitalization, this project will receive a subsidiary for next 2 years. Bio-Sight Capital supervises the entire project while the three partners are proceeding with research.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Oct 15, 2005
Words:158
Previous Article:Sanofi-aventis Japan Acquires Production and Sales Rights of Ancaron Antiarrhythmic Agent from Taisho Pharmaceutical.
Next Article:Mochida Pharmaceutical Adopts British Inpharmatica's In-silico ADME Suite, Admensa Interactive.


Related Articles
AnGes MG to Start Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.
Nikko Principal, AnGes MG Establish Fund for Pharmaceutical, Medical and Biotechnology Companies.
AnGes MG, Avontec Enter into Cross Licensing Agreement for Decoy Nucleic Acid Drug.
AnGes MG Patents HVJ Envelope Vector in US.
Hosokawa Micron, AnGes MG Succeed in Creating Composite Nanoparticle Contating NF-Kappa B Decoy Oligodeoxynucleotide.
AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.
AnGes MG, FALCO biosystems to Form Business Alliance in Gene Therapy Business.
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection.
AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.
AnGes MG Unveils Future Development Strategies for HGF Gene Medicine.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |